| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2018-09-13 | Oxford Biomedica (UK) | construction of new premises | Construction of new premises | |||
| 2018-09-12 | Imcheck Therapeutics (France) | chief scientific officer (CSO) | nomination | Cancer - Oncology - Autoimmune diseases | Nomination | |
| 2018-09-11 | Optibrium (UK) Intellegens (UK) | predictive modelling platform for drug discovery | development | Technology - Services | Development agreement | |
| 2018-09-11 | Akero Therapeutics (USA - CA) | president and chief executive officer | nomination | Liver diseases - Hepatic diseases | Nomination | |
| 2018-09-11 | SGS (Switzerland) | new testing capabilities at Lincolnshire facility | construction of new premises | Technology - Services | Construction of new premises | |
| 2018-09-11 | Amicus Therapeutics (USA - NJ) | member of the board of directors | nomination | Rare diseases - Genetic diseases - Metabolic diseases | Nomination | |
| 2018-09-10 | Affilofic (France) Samabriva (France) | Nanofitin®-conjugated biotherapeutics | lysosomal storage disorders | licensing | Rare diseases - Genetic diseases - Metabolic diseases | Licensing agreement |
| 2018-09-10 | Five Prime Therapeutics (USA - CA) SOLTI (Spain) | Reolysin® (pelareorep - human reovirus type 3 Dearing strain) | breast cancer | clinical research | Cancer - Oncology | Clinical research agreement |
| 2018-09-10 | Pieris Pharmaceuticals (USA - MA) | member of the board of directors | nomination | Cancer - Oncology | Nomination | |
| 2018-09-10 | Halozyme Therapeutics (USA - CA) | member of the board of directors | nomination | Cancer - Oncology | Nomination | |
| 2018-09-10 | Glythera, now Iksuda Therapeutics (UK) | restructuring - corporate name change | Cancer - Oncology | Restructuring | ||
| 2018-09-10 | Thrombogenics (Belgium) now Oxurion (Belgium) | Ophtalmological diseases | Restructuring | |||
| 2018-09-10 | Medivir (Sweden) | chief medical officer | nomination | Nomination | ||
| 2018-09-06 | Leukocare (Germany) Xellia Pharmaceuticals (Denmark) | new formulations for anti-infective products | research - development - R&D | Infectious diseases | Research agreement | |
| 2018-09-06 | Eli Lilly (USA - IN) Imperial College London (UK) UCL (UK) | Process Systems Engineering (PSE) methods | collaboration - research | Technology - Services | Research agreement | |
| 2018-09-06 | Oncolytics Biotech (Canada) Roche (Switzerland) | atezolizumab (Tecentriq®) | collaboration - supply agreement | Collaboration agreement | ||
| 2018-09-04 | Radius Health (USA - MA) | chief medical officer | nomination | Bone diseases - Cancer - Oncology | Nomination | |
| 2018-09-04 | Ziopharm Oncology (USA - MA) | member of the board of directors | nomination | Cancer - Oncology | Nomination | |
| 2018-09-04 | Tmunity Therapeutics, (USA - PA) | executive vice-president | nomination | Cancer - Oncology | Nomination | |
| 2018-08-30 | Eli Lilly (USA - IN) | senior vice president | nomination | Nomination |
